Specialty Pharmacy

High cost of research and development causes less investment by pharmaceutical firms.

A look back at the top stories of the week on Specialty Pharmacy Times.

Researchers predict the progression of the cancer based on its expression of IL13RA2.

Senate draft of the 2016 NDAA includes copay hikes for brand-name and non-formulary medications.

Researchers explore the use of probiotics to alter communication between brain and immune system.

Updated information includes drug-drug interaction.

Active surveillance increases in prevalence.

Despite inducing anti-HIV antibodies, vaccine in HVTN 505 trial still not protective.

Medication will be used as an add-on maintenance therapy in patients aged 12 years and older.

Pharmacists in Washington State can no longer cite religion to refuse to fill a prescription.

Diabetics are at greater risk for viral and bacterial infection compared with the remainder of the population.

One confirmed case and one probable case of definite progressive multifocal leukoencephalopathy reported in patients taking Gilenya for MS.

Study finds significant barriers to health care access, including stigmatization.

A lymphotoxin-beta receptor inhibitor may stop the spread of the disease.

Oxygen therapy use spikes since 2000.

Pharmacy expenditures account for 20% of total care costs for children with hemophilia.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Studies show inexpensive, generic drugs can help reduce breast cancer mortality in postmenopausal women.

Elevated risk found for heart arrhythmia, specifically atrial fibrillation.

Top stories of the week on Specialty Pharmacy Times.

Compound shows promise in reducing a precursor to RA.

Lithium chloride found to slow degradation.

Algorithm uses a computational model of the human body's protein networks.

Finacea Foam showed a greater reduction in the average nominal change of inflammatory lesion count.

Up to 13% of patients considered to have chronic obstructive pulmonary disease (COPD) under current criteria were recently found to be misdiagnosed.

The FDA has granted priority review to Merck's chronic hepatitis C virus (HCV) treatment candidate grazoprevir/elbasvir.

Liver damage progresses at a more rapid pace in patients with HIV.

Long-term survival results after 5 years of ipilimumab therapy in patients with advanced melanoma shows promise.